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INTRODUCTION: 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the 
most commonly used drugs in inflammatory diseases, 
since they are effective in management of pain, fever, 
redness, edema arising as a consequence of inflammatory 
mediator release. 
COX Iso-enzymes 
Until the beginning of the 1990s, it had been thought that 
there was only one COX enzyme. In 1990, rapid 
development of the studies in this field revealed that 
COX enzyme had two distinct isoforms with different 
genetic coding. Although both isoforms had similar 
amino acid sequence and catalytic activity, they were 
demonstrated to have different functions. These isoforms 
were named ‘constitutive’ COX-1 and ‘inducible’ COX-
2. COX-1 catalyzes the formation of cytoprotective 
prostaglandins (PGs) in thrombocytes, vascular 
endothelium, stomach mucosa, kidneys, pancreas, 
Langerhans islets, seminal vesicles, and brain. In the first 
step in the biosynthesis of prostanoids catalyzed by 
phospholipase A2 is arachidonic acid (AA) release from 
the membrane phospholipids. The second step is AA 
conversion by cyclooxygenase. First, the unstable PGG2 
is produced in the COX reaction, which is then 
immediately converted into PGH2 by the same enzyme in 
a peroxidase reaction. The end products of the AA 
metabolism are PGs, thromboxanes and prostacyclin. 
Induction of COX-2 by various growth factors, 
proinflammatory agents, endotoxins, mitogens, tumor 
agents indicates that this isoform may have a role in 
formation of pathological processes, such as 
inflammation. COX-1 products, prostaglandins (PGI2 
and PGE2), maintain integrity of gastrointestinal system 
(GIS) by reducing gastric acid secretion, increasing the 
thickness of mucus layer, stimulating bicarbonate 
secretion and enhancing mucosal blood flow. PGE2 
enhances mucus secretion by activating cAMP in gastric 
epithelial cells. Glucocorticoids and endogenous steroids 
can suppress the gene responsible for COX-2 synthesis. 
Drugs, which inhibit COX-1 more than COX-2, such as 
indomethacin, naproxen, ibuprofen, cause more severe 
damage to the gastric tissues. As a result of studies 
focused on reduction of the adverse effects of NSAIDs, 
selective COX-2 inhibitors, such as celecoxib and 
rofecoxib, have been developed.  
Schiff Base 
A Schiff base, named after Hugo Schiff, is a compound 
with a functional group that contains a carbon-
nitrogen double bond with the nitrogen atom connected 
to an aryl or alkyl group, not hydrogen.[1] Schiff bases in 
a broad sense have the general formula R1R2C=NR3, 
where R is an organic side chain. In this definition,Schiff 
base is synonymous with azomethine. Some restrict the 
term to the secondary aldimines (azomethines where the 
carbon is connected to a hydrogen atom), thus with the 
general formula RCH=NR'. [2] 
Hydrazones 
Hydrazones are a class of organic compounds with the 
structure R1R2C=NNH2.
 [6] They are related to ketones 
and aldehydes by the replacement of the oxygen with 
the NNH2 functional group. They are formed usually by 
the action of hydrazine on ketones or aldehydes. [7][8] 
 
ABSTRACTS: 
A mixture of phenyl acetic acid (10gm, 0.003mole) in acetone, dimethyl Sulphate (10.45ml, 0.007mole), anhydrous potassium 
carbonate (2.8gm, 0.02mol) was refluxed on a water bath for 2 hr with occasional stirring give methyl 2-phenylacetate(1), 
Methyl 2-phenylacetate (1.78gm, 0.01mole) in alcohol was refluxed with hydrazine hydrate (0.38gm, 0.01mole) for 8hrs 
formed 2-phenylacetohydrazide, A mixture of substituted benzaldehyde (1.22gm, 0.01mole) and 2-phenyl acetohydrazide 
(1.5gm, 0.01mole) were dissolved in methanol then two drops of conc. HCl were added as catalyst and stirred at room 
temperature for 2hr formed N'-(2-chlorobenzylidene)-2-phenylacetohydrazide,N'-(3,4,5-trimethoxybenzylidene)-2-
phenylacetohydrazide, N'-(furan-2-ylmethylene) -2-phenylacetohydrazide,  and N'-(3,4,5-trimethoxybenzylidene) -2-
phenylacetohydrazide 
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Sham. M. Sondhi. (2009) have report anti-inflammatory 
activity of some sulphono hydrozones. 
 
Sham. M. Sondhi. et.al. (2006) have report anti-
inflammatory and analgesic activity of some sulphono 
hydrozones. 
 
Vora. J.J. et.al. (2009) have reported synthesis and 
microbial studies of some novel schiff bases derivatives 
of 4–methyl pyridin–2–amine. 
 
Salgın G. U. et.al. (2007) have reported the synthesis of 
some 2 -[2-(5-methyl-2-benzoxazolinone-3-yl)-acetyl]-4-
substituted hydrazone derivatives with potent analgesic-
inflammatory and antimicrobial activity. 
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Our aim is to synthesize some newer schiff’s bases of 
phenyl acetic acid with potent anti-inflammatory activity 
with lesser side effects.   
The resarch work will be comprised of following steps. 
1. Synthesis phenyl acetic acid hydrazone derivatives. 
2. Physicochemical characterization of synthesized the 
structural features of these derivatives. 
MATERIAL AND METHODS 
Target Molecule:  
 
Synthetic scheme: 
 
Synthetic procedure:  
Synthesis of  -2a  
A mixture of 2-chloro benzaldehyde (1.39gm, 0.01mole)  
and 2-phenyl acetohydrazide (1.5gm, 0.01mole) were 
dissolved in methanol then two drops of conc. HCl were 
added as catalyst and stirred at room temperature for 3hr. 
the reaction mixture was poured into ice and filtered. The 
crude product so obtained was dried and recrystallized 
with methanol. 
 
N'-(2-chlorobenzylidene)-2-phenylacetohydrazide 
 
Synthesis of  -2b 
A mixture of   benzaldehyde (1.06gm, 0.01mole) and 2-
phenyl acetohydrazide (1.5gm, 0.01mole) were dissolved 
in methanol then two drops of conc. HCl were added as 
catalyst and stirred at room temperature for 4hr. the 
reaction mixture was poured into ice and filtered. The 
crude product so obtained was dried and recrystallized 
with methanol. 
 
N'-(3,4,5-trimethoxybenzylidene)-2-
phenylacetohydrazide 
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Synthesis of  -2c 
A mixture of furfuraldehyde (.96gm, 0.01mole) 2-phenyl 
acetohydrazide (1.5gm, 0.01mole) were dissolved in 
methanol then two drops of conc. HCl were added as 
catalyst and stirred at room temperature for 4 an half hr. 
the reaction mixture was poured into ice and filtered. The 
crude product so obtained was dried and recrystallized 
with methanol. 
 
N'-(furan-2-ylmethylene)-2-phenylacetohydrazide 
Synthesis of  -2d 
A mixture of p-hydroxy acetophenone (1.36gm, 
0.01mole) 2-phenyl acetohydrazide (1.5gm, 0.01mole) 
were dissolved in methanol then two drops of conc. HCl 
were added as catalyst and stirred at room temperature 
for 4 hr. the reaction mixture was poured into ice and 
filtered. The crude product so obtained was dried and 
recrystallized with methanol.  
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N'-(1-(4-hydroxyhenyl)ethylidene)-2-
phenylacetohydrazide 
Biological Evaluation: 
Anti-inflammatory activity:    
Animals Albino wistar rats, weighing 200-300 g, were 
used for experiments. The animals were kept in colony 
cages (6 rats each), maintained on a standard pellet diet 
with water, and left for 2 days for acclimatization before 
the experimental session. The food was withdrawn on the 
day before the experiment, but free access to water was 
allowed. All experiments were carried out according to 
the suggested ethical guidelines for the care of laboratory 
animals.   
Selection of experimental animals: Healthy Albino 
wistar male rats weighing between 200-300 gm were 
used for the evaluation of anti- inflammatory activity. 
The animals were obtained from Zydus Research Centre, 
Ahmedabad.   
Laboratory conditions: The rats were housed 
comfortably in a group of six in a single clean plastic 
cage with a metal frame lid on its top. Environmental 
room should be 22°C (± 3°C) relative humidity was at 
least 30 % and preferably not exceed 70 % other than 
during room cleaning the aim was to maintain between 
50-60%. Lighting was to be artificial, the sequence being 
12 hours light and 12 hours.   
Food and water: All animals had free access to water 
and standard palletized laboratory animal diet.   
Bedding: In the present study animals were provided 
with clean paddy husk bedding. Bedding was changed 
every alternate day to maintain proper hygienic 
conditions.   
Acute Toxicity Studies -The acute toxicity of 
naphthalene derivatives was determined by using Albino 
wistar rats (200-300 gm) before taking the anti-
inflammatory activity. The animals were fasted for 24 
hours prior to the experiment and up and down procedure 
(OECD Guideline no.425) method of CPCSEA was 
adopted for acute toxicity studies. Newly synthesized 
compounds suspended in tween-80 was administered to 
the group of rats (n=3) up to dose level of 10 mg/kg. 
Animals were placed in individual plastic cage and 
observed at least once daily for the first 30 minutes and 
periodically for 24 hours to observe for sign of toxicity.   
The anti-inflammatory activity of newly synthesized 
Hydrazide derivatives were carried out using 
carrageenan induced rat hind paw edema method.  
Method: - Inhibition of carrageenan induced 
inflammation in rat paw Animals used:-Albino wistar rat 
No. of animals used per group:-6 rats Dose of test 
compound:-3 mg/kg Dose of standard drug:-3 mg/kg 
(Indomethacin) Route of administration:-Intra peritoneal 
(suspended in 1% tween-80 solution)   
Requirements: - Instruments:-Mercury displacement 
plethysmometer. Inflammation inducing agent:-
carrageenan solution (1% w/v) in saline solution was 
prepared and injected (0.1 ml) in sub planter region to 
induce paw edema. Chemicals:-Tween-80 Standard 
drug:-Indomethacin (3 mg/kg) aqueous suspension was 
prepared using solution of tween-80 as a suspending 
agent. Test compounds:-suspension of compounds were 
prepared and administered intra peritoneal similar to that 
of standard drug.  
Apparatus: -Syringes (1 ml, 2 ml), sample tubes (to 
prepare suspension of test compounds).   
Experimental Design and Procedure:  - Weigh the 
animals and number them. Mark the animals with picric 
acid for individual animal identification. Divide rats into 
6 groups of 4 rats each. Note the initial paw volume of 
each rat by dipping just beyond tibio-tarsal junction by 
mercury displacement method, so that every time the 
paw is dipped in the mercury column up to the fixed 
mark to ensure constant paw volume. The animals were 
deprived of food overnight (allowed free access to water) 
and synthetic compounds were administered once before 
30 minutes the injection of carrageenan. Dose volume 
not exceeding 0.5ml/100gm intra peritoneal was 
administered.   
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Figure 1: Plethysmometer 
Group I:-The solvent control received normal saline. 
Group II:-Positive control received Diclofenac Sodium 
(3 mg/kg). 
 Group III:-Received Hydrazide derivative at a dose of 3 
mg/kg suspended in 1% w/v tween-80.  
Group IV:-Received Hydrazide derivative- at a dose of 3 
mg/kg suspended in 1% w/v tween-80 Group  
V:-Received Hydrazide derivative- at a dose of 3 mg/kg 
suspended in 1% w/v tween-80.   
Group VI:-Received Hydrazide derivative- at a dose of 
3 mg/kg suspended in 1% w/v tween-80.  
After 30 minutes of test compound administration, 0.1 
ml of 1% w/v of carrageenan in normal saline was 
injected in to the sub planter region of the left hind paw 
of rat. Immediately after the carrageenan injection, the 
volume of its displacement was measured using 
plethysmometer. The reading was recorded at 0, ½, 1, 2, 
3 hrs.    
 
Figure 2: Carrageenan Induced Inflammation 
The % inhibition of edema was calculated at the end of 3 
hrs by using the formula[51] Percent (%) inhibition = 1 – 
Vt/Vc X 100,  Where   
  Vt- edema volume in test group,                 
  Vc-edema volume in control group   
Results were expressed as mean ± SEM (Standard Error 
of Mean). 
  
 
RESULT: 
Screening of Anti-Inflammatory Activity 
Table 1:-Screening of Anti-inflammatory activity in Albino wistar rat 
COMPOUNDS VOLUME OF EDEMA % INHIBITION 
 
Control(DMSO) .09375-±0.00625 0 
 
Diclofenac sodium .03125±0.00625 66.66 
 
Comps 2a  .0500±0.01768 46.69 
 
2b .0375±0.007217 46.66 
 
2c .0500±0.01768 56.69 
 
2d .05625±0.01573 52.01 
 
 
The pharmacological screening of the synthesized 
compounds showed anti-inflammatory activity ranging 
from 33.33 to 66.66 % inhibition of rat paw edema 
volume after 3 hours, whereas the standard drug 
Diclofenac sodium showed 66.66 % inhibition of rat paw 
edema volume after 3 hours.  
The compound –2c and 2d was found to be nearly more 
potent then Diclofenac sodium which is used as standard 
drug. A compound – 2a and 2b has shown less activity 
then Diclofenac sodium. Compounds SE and SJ shown 
more potent activity than compound –2a and 2d  and 
Diclofenac sodium. 
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Physical characteristics:  
Compound code Mol. Formula % yield Melting point Rf value 
2a C15H13N2OCl 75% 60.5 0.90 
2b C13H12N2O2 65.29% 55.5 0.85 
2c C18H20N2O4 44.05% 50.5 0.72 
2d C17H17N2O2 46.55% 71 0.60 
 
Spectral analysis: 
Compound code IR (cm-
1
) Mass (m/e) 1
H
-NMR 
2a 3564.58(OH), 3105.18(Ar-CH), 
3104.44(NH), 1693.38(C=O), 
1503.57(C=N), 1125.35(OCH3) 
M+ 279 
Base peak 
261.1 
8.6(s,1H,NH), 7.2-8.0(m,9H,Ar-H), 
6.7(s,2H,CH2), 1.2(s1H,CH),   
 
2b 3469.70(OH), 3301.91(NH), 
3301.91(NH), 3195.91(NH), 
3031.89(Ar-CH), 1701.10(C=O), 
1546.8(CH)  
M+ 239 
Base peak 208 
9.8(s,1H,OH), 8.5(s,1H,NH), 7.2-
7.8(m,9H,Ar-H),  5.5(s,2H,CH2), 
1.6(s,1H,CH) 
 
2c 3124.95(NH), 2923.24(Ar-CH), 
1679.12(C=O), 1632.30(C=N)  
M+ 267 
Base peak 220 
8.9(s,1H,NH), 7.7-8.3(m,9H,Ar-H), 
7.09(s,2H,CH2), 1.47(s,1H,CH), 
3.1(s,6H,N(CH3)2) 
2d 3359.90(NH),  3199.24(NH), 
3097.28(Ar-CH), 1696.54(C=O), 
1516.19(C=N), 1299.60(N(CH3)2) 
M+ 272 
Base peak 
235.5 
8.3(s1H,NH), 7.2-8.2(m,7H,Ar-H), 
7.0(s,2H,CH2), 4.0(s,9H,OCH3) 
 
 
CONCLUSION: 
From the above data I found the comp-2C and 2d have near the potent drugs as I used Diclofenac Sodium.  
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